Recent Updates
Recently added Catalysts

GARDASIL9

Phase 1

Healthy | Monoclonal antibody | Other |Merck & Company, Inc.|Last Updated: Aug 3, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment72
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06623409Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).PHASE1 ACTIVE NOT_RECRUITING 72Nov 12, 2024Nov 20, 2026Aug 3, 20255 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants Who Experience a Solicited Injection-Site Adverse Event (AE)
Up to approximately 6 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Number of Participants Who Experience a Solicited Systemic AE
Up to approximately 6 months

Solicited systemic AEs include headache, fatigue, nausea, dizziness, muscle aches, joint pain.

Immediate Reactions Occurring Within 30 Minutes After Any Vaccination
Up to approximately 6 months

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Number of Participants Who Experienced Unsolicited AEs
Up to approximately 7 months

An unsolicited AE is an AE that was not solicited using a vaccine report card (VRC) and that is communicated by a participant (or their legally acceptable representative, if applicable). Unsolicited AEs include serious and nonserious AEs.

Number of Participants Who Experienced a Serious Adverse Event
Up to approximately 18 months

Serious adverse events (SAEs) include adverse events that result in any of the following outcomes: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect.

Number of Participants Who Experienced a Medically-Attended AE
Up to approximately 18 months

AEs in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency department visit, office visit, or an urgent care visit with any medical personnel for any reason. Routine visits are not considered medically-attended adverse events (MAAEs). Examples of routine visits include physical examination, wellness visits, or vaccinations.

Number of Participants Who Experienced an Event of Clinical Interest
Up to approximately 18 months

Events of clinical interest (ECIs) are defined as an overdose of Sponsor's product, drug-induced liver injury events, or potential immune-mediated diseases (pIMDs).

Secondary Endpoints
Total Immunoglobulin G (IgG) Geometric Mean Ratios (GMRs) for anti-HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58
Up to approximately 7 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelSEQUENTIAL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
GARDASIL®9 (G9)ACTIVE_COMPARATORParticipants will receive vaccinations with G9.
V540BEXPERIMENTALParticipants will receive vaccinations with V540B.
Interventions
NameTypeDescription
GARDASIL®9 (G9)BIOLOGICALSuspension administered via intramuscular (IM) injection
V540BBIOLOGICALExperimental vaccine and adjuvant administered via IM injection
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexALL
Healthy VolunteersYes
Study Sites5

Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is in good health based on medical history, physical examination, vital sign (VS) measurements and electrocardiograms (ECGs) performed before randomization. Exclusion Criteria: The key exclusion criter...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06623409primaryCompletionDate: changed
LOWMay 24, 2026NCT06623409studyFirstPostDate: changed